{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:36:50Z","timestamp":1769204210554,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Benzydamine for oromucosal use is indicated in the relief of pain and irritation of the mouth and throat. It is an indazole derivative, non-steroidal anti-inflammatory drug, with combined local anesthetic and analgesic properties, and antiseptic activity, marketed under the brand name \u201cTantum Verde\u201d. The aim of this study was to explore knowledge and prescriptive\/advising attitudes among general practitioners (GPs) and pharmacists (PHs) with regard to the topical treatment of sore throat and other irritative\/inflammatory conditions of the oropharynx, with a focus on benzydamine. These findings could be important to increase awareness on benzydamine efficacy in sore throat and stomatological conditions, and to reinforce knowledge on the characteristics of benzydamine and its mechanisms of action among healthcare professionals (pediatricians, otolaryngologists, oncologists, etc.).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>An online questionnaire survey was performed among PHs and GPs in four European countries (Italy, Germany, Russia and Poland).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both GPs and PHs proved to have an excellent knowledge and mastery of the constituents effective against oral symptoms. Among all the principles, benzydamine hydrochloride is the most recognized as certainly suitable for the topical treatment of sore throat symptoms and various inflammatory\/irritative conditions of the oral cavity. It is recommended by about 90% of PHs and prescribed by 80% of GPs, mainly to solve the ailments caused by sore throats and stomatitis, especially for its anti-inflammatory, analgesic and anesthetic characteristics. Also in the pediatric field, benzydamine hydrochloride is recommended: among GPs, a high percentage (about 40%) prescribes it like the remedies based on dichlorobenzyl alcohol-sodium benzoate, which are instead more often recommended by PHs (44% against 37%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although the public has a lot of confidence in this treatment, GPs and PHs do not recommend\/prescribe benzydamine as a first-line treatment of sore throat and other irritative\/inflammatory conditions of the oropharynx. To increase the knowledge of benzydamine among these healthcare professionals, it would be important to emphasize its characteristics and the different irritative\/inflammatory conditions of the oropharynx in which it can be used.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12875-022-01762-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:09:12Z","timestamp":1655496552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Benzydamine hydrochloride for the treatment of sore throat and irritative\/inflammatory conditions of the oropharynx: a cross-national survey among pharmacists and general practitioners"],"prefix":"10.1186","volume":"23","author":[{"given":"Desiderio","family":"Passali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Felice","family":"Arezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"De Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Forte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalina","family":"Jablko-Musial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"M\u00f6sges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"2","key":"1762_CR1","first-page":"127","volume":"61","author":"RS Turnbull","year":"1995","unstructured":"Turnbull RS. Benzydamine Hydrochloride (Tantum) in the management of oral inflammatory conditions. J Can Dent Assoc. 1995;61(2):127\u201334.","journal-title":"J Can Dent Assoc"},{"key":"1762_CR2","first-page":"734","volume":"23","author":"S Simard-Savoie","year":"1978","unstructured":"Simard-Savoie S, Forest D. Topical anaesthetic activity of benzydamine. Curr Ther Res. 1978;23:734\u201345.","journal-title":"Curr Ther Res"},{"issue":"6","key":"1762_CR3","first-page":"243","volume":"19","author":"DE Griswold","year":"1993","unstructured":"Griswold DE, Hillegass LM, Breton JJ, Esser KM, Adams JL. Differentiation in vivo of classical non-steroidal anti-inflammatory drugs from cytokine suppressive anti-inflammatory drugs and other pharmacological classes using mouse tumour necrosis factor alpha production. Drugs Exp Clin Res. 1993;19(6):243\u20138.","journal-title":"Drugs Exp Clin Res"},{"issue":"2","key":"1762_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0014-2999(68)90069-1","volume":"3","author":"R Lisciani","year":"1968","unstructured":"Lisciani R, Barcellona PS, Silvestrini B. Researches on the topical activity of benzydamine. Eur J Pharmacol. 1968;3(2):157\u201362.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1762_CR5","first-page":"105","volume":"10","author":"RG Landry","year":"1988","unstructured":"Landry RG, Turnbull RS, Howley T. Effectiveness of benzydamine HCl in the treatment of periodontal post-surgical patients\u201d. Res Clin Forums. 1988;10(8):105\u201311.","journal-title":"Res Clin Forums"},{"issue":"2","key":"1762_CR6","first-page":"127","volume":"61","author":"RS Turnbul","year":"1995","unstructured":"Turnbul RS. Benzydamine Hydrochloride (Tantum) in the management of oral inflammatory conditions. Journal Can Den Assoc. 1995;61(2):127\u201334.","journal-title":"Journal Can Den Assoc"},{"issue":"6","key":"1762_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3109\/10837450902882351","volume":"14","author":"SY Karavana","year":"2009","unstructured":"Karavana SY, G\u00fcneri P, Ertan G. Benzydamine hydrochloride buccalbioadhesive gels designed for oral ulcers: preparation, rheological, textural, mucoadhesive and release properties. Pharm Dev Technol. 2009;14(6):623\u201331.","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"1762_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1213\/01.ane.0000231637.28427.00","volume":"103","author":"A Agarwal","year":"2006","unstructured":"Agarwal A, Nath SS, Goswami D, Gupta D, Dhiraaj S, Singh PK. An evaluation of the efficacy of aspirin and benzydamine hydrochloride gargle for attenuating postoperative sore throat: a prospective, randomized, singleblind study. Anesth Analg. 2006;103(4):1001\u20133.","journal-title":"Anesth Analg"},{"issue":"5","key":"1762_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00002820-200609000-00012","volume":"29","author":"K Kin-Fong Cheng","year":"2006","unstructured":"Kin-Fong Cheng K, KaTsuiYuenet J. A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs. 2006;29(5):423\u201330.","journal-title":"Cancer Nurs"},{"issue":"5","key":"1762_CR10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00520-016-3548-9","volume":"25","author":"M Rastogi","year":"2017","unstructured":"Rastogi M, Khurana R, Revannasiddaiah S, Jaiswal I, Nanda SS, Gupta P, et al. Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy. Support Care Cancer. 2017;25(5):1439\u201343.","journal-title":"Support Care Cancer"},{"issue":"459","key":"1762_CR11","first-page":"817","volume":"50","author":"M Thomas","year":"2000","unstructured":"Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract. 2000;50(459):817\u201320.","journal-title":"Br J Gen Pract"},{"issue":"6","key":"1762_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1370\/afm.609","volume":"4","author":"ML van Driel","year":"2006","unstructured":"van Driel ML, De Sutter A, Deveugele M, Peersman W, Butler CC, De Meyere M, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann Fam Med. 2006;4(6):494\u20139.","journal-title":"Ann Fam Med"},{"issue":"Suppl 1","key":"1762_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03766.x","volume":"18","author":"C Pelucchi","year":"2012","unstructured":"Pelucchi C, Grigoryan L, Galeone C, Esposito S, Huovinen P, Little P, et al. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012;18(Suppl 1):1\u201328.","journal-title":"Clin Microbiol Infect"},{"key":"1762_CR14","first-page":"127","volume":"280","author":"S Marshall","year":"2008","unstructured":"Marshall S. Giving advice on sore throats. Pharm J. 2008;280:127\u201330.","journal-title":"Pharm J"},{"issue":"1","key":"1762_CR15","first-page":"25","volume":"12","author":"M Roxas","year":"2007","unstructured":"Roxas M, Jurenka J. Colds and influenza: a review of diagnosis and conventional botanical and nutritional considerations. Altern Med Rev. 2007;12(1):25\u201348.","journal-title":"Altern Med Rev"},{"issue":"1","key":"1762_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.aaen.2004.10.008","volume":"13","author":"A Summers","year":"2005","unstructured":"Summers A. Sore throats. Accid Emerg Nurs. 2005;13(1):15\u20137.","journal-title":"Accid Emerg Nurs"},{"issue":"11","key":"1762_CR17","first-page":"1961","volume":"53","author":"GJ Worrall","year":"2007","unstructured":"Worrall GJ. Acute sore throat. Can Fam Physician. 2007;53(11):1961\u20132.","journal-title":"Can Fam Physician"},{"issue":"4","key":"1762_CR18","first-page":"CD000023","volume":"2013","author":"CB Del Mar","year":"2006","unstructured":"Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2006;2013(4):CD000023.","journal-title":"Cochrane Database Syst Rev"},{"key":"1762_CR19","unstructured":"Centre for Clinical Practice at NICE (UK) Respiratory Tract Infections - Antibiotic Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care. London: National Institute for Health and Clinical Excellence (UK); 2008. National Institute for Health and Clinical Excellence: Guidance. Available from: https:\/\/www.nice.org.uk\/guidance\/cg69"},{"issue":"1","key":"1762_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s005990070028","volume":"30","author":"M Sironi","year":"2000","unstructured":"Sironi M, Massimiliano L, Transidico P, Pinza M, Sozzani S, Mantovani A, et al. Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist. Int J Clin Lab Res. 2000;30(1):17\u20139.","journal-title":"Int J Clin Lab Res"},{"key":"1762_CR21","unstructured":"Mangano G, Apicella C, Vitiello M, Milanese C, Polenzani L. Benzydamine Local Anesthetic Activity And [3H]-Batrachotoxin Binding Sites. Poster presented to 31st National Congress of the Italian Society of Pharmacology, Trieste, Italy, 26\u201329 June, 2003. Available from: https:\/\/www.pharmtox.org\/sif_unito\/archivio\/cong31\/absweb\/mangano_g.pdf."},{"issue":"6","key":"1762_CR22","first-page":"851","volume":"67","author":"S Mathivanan","year":"2016","unstructured":"Mathivanan S, de la Torre-Martinez R, Wolf C, Mangano G, Polenzani L, Milanese C, et al. Effect of econazole and benzydamine on sensory neurons in culture. J Physiol Pharmacol. 2016;67(6):851\u20138.","journal-title":"J Physiol Pharmacol"},{"issue":"2","key":"1762_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18433\/J31309","volume":"15","author":"D McNally","year":"2012","unstructured":"McNally D, Shephard A, Field E. Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol\/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection. J Pharm Pharm Sci. 2012;15(2):281\u201394.","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"1762_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.11124\/JBISRIR-2016-003034","volume":"15","author":"TW Tan","year":"2017","unstructured":"Tan TW, Chen BC, Tan HL, Chang CM. Effectiveness of amylmetacresol and 2,4-dichlorobenzyl alcohol throat lozenges in patients with acute sore throat due to upper respiratory tract infection: a systematic review protocol. JBI Database System Rev Implement Rep. 2017;15(4):862\u201372.","journal-title":"JBI Database System Rev Implement Rep"},{"issue":"6","key":"1762_CR25","first-page":"1","volume":"12","author":"AG Wade","year":"2011","unstructured":"Wade AG, Morris C, Shephard A, Crawford GM, Goulder MA. A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC\/DCBA Warm lozenge or AMC\/ DCBA Cool lozenge in the relief of acute sore throat. BMC Fam Pract. 2011;12(6):1\u201314.","journal-title":"BMC Fam Pract"},{"issue":"4","key":"1762_CR26","doi-asserted-by":"publisher","first-page":"JC2","DOI":"10.7326\/0003-4819-153-4-201008170-02006","volume":"153","author":"MJ Thomas","year":"2010","unstructured":"Thomas MJ, ACP Journal Club. Amylmetacresol and 2,4- dichlorobenzyl alcohol lozenges were better than placebo lozenges for relief of acute sore throat. Ann Intern Med. 2010;153(4):JC2-6.","journal-title":"Ann Intern Med."},{"issue":"2","key":"1762_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1742-1241.2009.02230.x","volume":"64","author":"D McNally","year":"2010","unstructured":"McNally D, Simpson M, Morris C, Shephard A, Goulder M. Rapid relief of acute sore throat with AMC\/DCBA throat lozenges: randomized controlled-trial. Int J Clin Pract. 2010;64(2):194\u2013207.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1762_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/095632020501600205","volume":"16","author":"JS Oxford","year":"2005","unstructured":"Oxford JS, Lambkin R, Gibb I, Balasingam S, Chan C, Catchpole A. A throat lozenge containing amylmetacresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus influenza A and SARs-CoV. Antivir Chem Chemother. 2005;16(2):129\u201334.","journal-title":"Antivir Chem Chemother"},{"issue":"2","key":"1762_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40268-013-0012-x","volume":"13","author":"A Thompson","year":"2013","unstructured":"Thompson A, Reader S, Field E, Shephard A. Open-label taste-testing study to evaluate the acceptability of both strawberry-flavored and orange-flavored amylmetacresol\/2,4-dichlorobenzyl alcohol throat lozenges in healthy children. Drugs R D. 2013;13(2):101\u20137.","journal-title":"Drugs R D"},{"issue":"4","key":"1762_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1742-1241.2008.01984.x","volume":"63","author":"M Limb","year":"2009","unstructured":"Limb M, Connor A, Pickford M, Church A, Mamman R, Reader S, et al. Scintigraphy can be used to compare efficacy of sore throat formulations. Int J Clin Pract. 2009;63(4):606\u201312.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1762_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1067\/mcp.2002.124079","volume":"71","author":"BP Schachtel","year":"2002","unstructured":"Schachtel BP, Homan HD, Gibb IA, Christian J. Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. Clin Pharmacol Ther. 2002;71(5):375\u201380.","journal-title":"Clin Pharmacol Ther"},{"key":"1762_CR32","first-page":"188","volume":"118","author":"K Kr\u00fcger","year":"2021","unstructured":"Kr\u00fcger K, T\u00f6pfner N, Berner R, Windfuhr J, Oltrogge JH. Clinical practice guideline: sore throat. Dtsch Arztebl Int. 2021;118:188\u201394.","journal-title":"Dtsch Arztebl Int"},{"key":"1762_CR33","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of sore throat and indications for tonsillectomy. A national clinical guideline 2010. Available from: https:\/\/www.sign.ac.uk\/media\/1055\/sign117.pdf"},{"issue":"1","key":"1762_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12875-019-0970-3","volume":"20","author":"KB Reinholdt","year":"2019","unstructured":"Reinholdt KB, Rusan M, Hansen PR, Klug TE. Management of sore throat in Danish general practices. BMC Fam Pract. 2019;20(1):75.","journal-title":"BMC Fam Pract"},{"key":"1762_CR35","unstructured":"Farah B, Visintini S. Benzydamine for acute sore throat: A review of clinical effectiveness and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep 21.CADTH Rapid Response Reports. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537954\/"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-022-01762-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:09:25Z","timestamp":1655496565000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-022-01762-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1186\/s12875-022-01762-3","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the European Data Protection Rules with informed consent from all participants. According to the article 1, paragraph 1, of the legislative decree n. 211 of 2003 (legislation implementing the European Directive 2001\/20 \/ EC on the application of good clinical practice in the execution of clinical trials of medicinal products for clinical use) and according to the Sect.\u00a01.3 of the EphMRA (European Pharmaceutical Market Research Association) Code of Conduct, no formal ethics approval was needed since no research on human tissue or other biological material was performed, as stated by the research marketing company that conducted the survey. The participating general practitioners and pharmacists were informed about the use and publication of their anonymized data for this study. Participation in the study was voluntary. Returning the completed questionnaire was interpreted as informed consent to participate in the study. No incentives were offered.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Dr. M\u00f6sges reports personal fees from Angelini Pharma, during the conduct of the study; personal fees from ALK, grants from ASIT biotech, personal fees from allergopharma, personal fees from Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non-financial support from Lofarma, non-financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, personal fees from Hexal, personal fees from Servier, personal fees from Klosterfrau, non-financial support from Atmos, personal fees from Bayer, non-financial support from Bionorica, personal fees from FAES, personal fees from GSK, personal fees from MSD, personal fees from Johnson&Johnson, personal fees from Meda, personal fees and non-financial support from Novartis, non-financial support from Otonomy, personal fees from Stada, personal fees from UCB, non-financial support from Ferrero, grants from BitopAG, grants from Hulka, personal fees from Nuvo, grants and personal fees from Ursapharm, personal fees from Menarini, personal fees from Mundipharma, personal fees from Pohl-Boskamp, grants from Inmunotek, grants from Cassella-med GmbH & Co. KG, personal fees from Laboratoire de la Mer, personal fees from Sidroga, grants and personal fees from HAL BV, personal fees from Lek, personal fees from PRO-AdWise, outside the submitted work.Passali D., Arezzo M. F., De Rose A., De Simone G., Forte G., Jablko-Musial M. declares no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}